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Objectives The goal of the study was to clarify the impact of post-procedural aortic regurgitation
(post-AR) grade 2/4 on clinical outcomes.
Background Post-AR 2/4 is known to be associated with poor short- to midterm outcome after
transcatheter aortic valve implantation (TAVI).
Methods We compared clinical outcomes in 400 consecutive TAVI recipients according to
post-AR grade: grade 0 or 1 (group 1  74.8%), grade 2 (group 2  22.2%), or grade 3 or 4
(group 3  3.0%).
esults The mean age was similar in the 3 groups (83.4  6.1 years) as was the logistic EuroSCORE
22.5  11.4%, 24.5  11.6%, and 21.5  9.4%, p  0.28) and annulus size (22.0  1.8, 22.2  2.1,
and 22.5  2.1 mm, p  0.53). The Edwards valve was most frequently used in group 1 compared
with groups 2 and 3 (89.3%, 78.7%, and 83.3%, p  0.03), and the implanted valve size was similar
in all groups (25.6  2.0, 25.4  2.2, and 25.5  2.2 mm, respectively, p  0.69). Post-dilation was
required more frequently in group 3 (4.7%, 24.1%, and 50.0%, respectively, p  0.01). Post-
procedural increase in mitral regurgitation was in line with the post-AR grade (0.78  0.73, 1.22 
0.80, and 1.89  0.78, respectively, p  0.01). Despite the absence of difference in 30-day mor-
tality, longer-term outcome was signiﬁcantly poorer in patients with AR grade 2 than in those
with AR grade 0 or 1 (log-rank p  0.01), albeit better than in patients with AR grade 3 or 4
(p  0.04), regardless of TAVI type and left ventricular function. Post-AR 2/4 was also identi-
ﬁed as an independent predictor of mid- to long-term mortality (hazard ratio: 1.68, 95% conﬁ-
dence interval: 1.21 to 1.44, p  0.01).
onclusions Post-AR grade 2/4 after TAVI is associated with worse outcome compared with grade
or 1. Careful valve selection and post-dilation when required to avoid post-AR grade 2 may con-
ribute to improved clinical outcome after TAVI. (J Am Coll Cardiol Intv 2012;5:1247–56) © 2012 by
he American College of Cardiology Foundation
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1248Transcatheter aortic valve implantation (TAVI) has
emerged as a viable therapeutic option for patients with
severe symptomatic aortic stenosis (AS) who are ineligible
or at high-risk for conventional surgical aortic valve replace-
ment (1–3). Although this technique has reached relative
maturity, further optimization of patient selection and
device implantation is necessary. TAVI is a procedure
whereby a stent-framed bioprosthesis is placed (positioned,
deployed) by compression and without resection of the
native aortic valve. This may result in a gap being created
between the implanted device and the native aortic valve in
instances where the native valve or its annulus is calcified,
thus leading to post-procedural aortic regurgitation (AR)
(4). Significant post-procedural AR (grade 2/4) after
TAVI was recently identified as a predictor of 1-year
mortality (5). However, the differences in terms of impact
on the clinical outcome between
post-procedural AR grade 2 and
grade 0 or 1 were not sufficiently
documented. Post-dilation has
been proposed to reduce the de-
gree of post-procedural AR.
However, this strategy may in-
crease the risk of aortic rupture,
central valvular regurgitation, ac-
celerated degenerative process, or
possibly stroke. Given the poten-
tial complications involved, the
degree of AR warranting post-
dilation should be carefully deter-
mined.
The objective of this study was
to clarify the impact of each grade
of post-procedural AR on clinical
outcomes and provide guidance
for optimal valve size selection
and post-dilation strategy.
Methods
Study population and design. From October 2006, all pa-
ients with severe symptomatic AS treated with TAVI at
ur institution were prospectively included in our TAVI
atabase. Patients with severe symptomatic AS (valve area
1.0 cm2) were considered candidates for TAVI if they had
logistic European System for Cardiac Operative Risk
valuation score (EuroSCORE) 20%, if surgery was
eemed to carry excessive risk due to significant comorbidi-
ies, or if other risk factors not captured by these scoring
ystems (e.g., porcelain aorta) were present. The decision to
roceed with TAVI was discussed by a dedicated heart
eam, including experienced clinical and interventional car-
iologists, cardiovascular surgeons, and anesthesiologists.
Abbreviations
and Acronyms
AR  aortic regurgitation
AS  aortic stenosis
CI  confidence interval
CT  computed tomography
dAR  degree of aortic
regurgitation
Diam-TEE  annulus
diameter measured by
transesophageal
echocardiography
HR  hazard ratio
LVEF  left ventricular
ejection fraction
MR  mitral regurgitation
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiographyll patients selected for TAVI underwent screening, phys-cal examination, transthoracic and transesophageal echo-
ardiography (TEE), baseline laboratory tests, and coronary
ngiography. Assessment of the aortic annulus size was
erformed by TEE and/or multidetector computed tomog-
aphy (CT).
Between October 2006 and October 2011, a total of 424
atients were included in our TAVI database. TEE-guided
alve sizing was performed during the early stages of our
xperience, and CT-guided sizing has been progressively
ntroduced since 2009.
Twenty-four patients were excluded from this analysis
ecause they either did not receive TAVI or died during or
ithin 24 h of the procedure due to reasons that were
bviously not related to post-procedural AR.
Procedural characteristics and clinical outcomes were
ompared in the remaining 400 consecutive TAVI recipi-
nts according to post-procedural AR grades: grade 0 or 1
group 1), grade 2 (group 2), or grade 3 or 4 (group 3).
All patients agreed to participate in the study, and written
nformed consent was obtained in all cases.
Vascular access and valve selection. Patients were selected
o undergo TAVI via the transfemoral approach or alterna-
ive approaches depending on the size, calcification and
ortuosity of the iliofemoral arterial access. The type of
ioprosthesis was selected according to the diameter of the
ortic annulus which, in the early phases of our experience,
as systematically measured using TEE (Diam-TEE).
ore recently, the mean annulus diameter has been calcu-
ated using multidetector CT (mDiam-CT) (6). The Ed-
ards valve (Edwards Lifesciences, Irvine, California) was
sed in patients with a diameter of 18 to 24.5 mm and the
oreValve (Medtronic, Minneapolis, Minnesota) was se-
ected for annular diameters of 20 to 26.5 mm via the
ransfemoral approach. For historical reasons (the Edwards
alve was first introduced in 2006), the Edwards valve was
sed preferentially in patients with an annulus diameter of
0 to 24.5 mm, who were amenable to treatment with either
alve. The CoreValve prosthesis was implanted in patients
hose annulus size was 24.5 mm, or patients with
orderline iliofemoral access when 18- and 19-F Edwards
heaths were not available.
The trans-subclavian or transaortic approach was used as
n alternative in cases of unsuitable femoral arterial access in
ecipients of the CoreValve with annular diameters of 20 to
8 mm, and the transapical, trans-subclavian, or transaortic
oute as the alternative to suboptimal femoral access with
he Edwards valve in patients with annular diameters of 18
o 26.5 mm.
Echocardiography. A detailed transthoracic echocardiogra-
phy and TEE examination was performed in all cases during
initial patient assessment by experienced echocardiogra-
phers by means of the Philips ie33 ultrasound system
(Philips Medical, Amsterdam, the Netherlands) and a
dedicated Philips probe. The aortic annulus diameter was
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1249defined as the distance (in millimeters) between the hinge
points of the aortic valve leaflets, and was measured in the
long-axis view of the aortic valve at end-systole using TEE,
according to published recommendations (7,8). In all cases,
the diameter was measured 3 times, and the mean value was
used for TEE valve sizing. The degree of pre- and post-
procedural AR was measured with color Doppler using
transthoracic echocardiography by 2 independent experi-
enced echocardiographers, who were unaware of the proce-
dural information according to current guidelines (8) and
as translated into a semiquantitative grade as 0  none,
 trivial, 2  mild, 3  moderate, and 4  severe. All
oppler measurements were evaluated as the average of at
east 3 cycles in patients with sinus rhythm or more than 5
ycles in those with atrial fibrillation. Consensus was ob-
ained between 2 operators when there were discrepancies.
n Kaplan-Meier survival analysis, we also evaluated the
hange in the degree of aortic regurgitation (dAR) in the
roups as follows; “AR improved”: (dAR  2 or 3), “AR
o or little change”: (dAR  1 to 1) and “AR wors-
ned”: (dAR 2 or 3).
Procedures. Before TAVI, patients were on aspirin (75 to
60 mg) and clopidogrel (75 mg) daily, or were given a
oading dose of clopidogrel (300 to 600 mg) before or
mmediately after the procedure. From January 2010, pa-
ients on warfarin were only administered a combination of
spirin and warfarin after TAVI. A bolus of intravenous
eparin (70 IU/kg) was administered at the start of each
rocedure to achieve an activated clotting time of 250 to
00 s, and the activated clotting time was measured every 30
in thereafter. Transfemoral procedures were performed by
xperienced interventional cardiologists, and nontransfemo-
al procedures by a team of at least 1 cardiac surgeon and 1
nterventional cardiologist according to our standard oper-
ting procedures, as previously described (9,10).
Post-procedural care. All patients were observed in the
ntensive care unit for at least 24 h after Edwards valve
mplantation or 72 h after CoreValve implantation (in
atients without previous pacemaker placement). Dual an-
iplatelet therapy was continued for 6 months, and thereaf-
er, aspirin was continued indefinitely.
Follow-up. After TAVI, all patients were assessed by a
physician at 1, 3, 6, and 12 months post-operatively and
annually thereafter. Additional follow-up data were col-
lected through telephone interviews and contact with pa-
tients’ family physicians, except for 1 patient lost during
follow-up.
Endpoint deﬁnitions. The primary endpoint of this study
as all-cause mortality over the duration of the study.
ll-cause mortality, combined 30-day safety endpoints, and
evice success as defined by the Valve Academic Research
onsortium criteria (11), were also evaluated.
Statistical analysis. Quantitative variables are expressed as
mean  standard deviation, and qualitative variables asnumbers and percentages. Comparison of quantitative vari-
ables was performed with a 1-way analysis of variance or
Kruskal-Wallis test, depending on variable distribution. A
Bonferroni test was used to define statistical differences
between the groups. The Wilcoxon rank sum test was used
to compare pre- and post-procedural MR in each group of
paired data. The chi-square test or Fisher exact test was used
to compare qualitative variables. Survival analyses were
performed by Kaplan-Meier analysis.
A Cox regression analysis was used to examine the
univariable association of clinical, procedural and echocar-
diographic variables with long-term mortality. Multivari-
able analysis, including all variables with p value 0.05 in
the univariate analysis, was performed to determine the
predictors of long-term mortality.
Statistical significance was defined as p  0.05. The data
were analyzed with SPSS Statistics 20.0 (SPSS, Chicago,
Illinois).
Results
Between October 2006 and October 2011, TAVI was
carried out in 400 of 424 patients initially scheduled to
undergo this procedure at our institution.
Twenty-four patients were excluded from the current
analysis: 11 patients who did not receive a valve (1 case of
recurrent ventricular fibrillation after balloon valvuloplasty
and before valve deployment; 1 abdominal aortic rupture
before TAVI implantation; 1 case of failed crossing of a
native valve with a bioprosthesis; 4 cases of failed arterial
access, 4 cases of valve migration), 13 patients who died
during or within 24 h of the procedure due to patently
different reasons (1 left main occlusion, 3 annulus ruptures,
2 cardiogenic shocks during the procedure due to low left
ventricular ejection fraction, 1 cerebrovascular accident, 2
cardiac tamponade, and 4 access site complications).
The remaining 400 patients received either the Edwards
valve (n  347) or the CoreValve Revalving system (n 
53). The cohort was divided into 3 groups according to the
degree of post-procedural AR as follows: group 1: AR grade
0 or 1 (299 cases), group 2: AR grade 2 (89), and group 3:
AR grade 3 or 4 (12), and the patient characteristics and
clinical outcomes were compared. Post-procedural AR
mostly consisted of paraprosthetic leak, and no central AR
grade 2 was observed in this cohort.
Patient characteristics. The mean age of the entire popula-
tion was 83.4 6.1 years (Table 1). Congestive heart failure
class III/IV was prevalent in 86.8%, coronary artery disease
in 59.3%, previous coronary artery bypass grafting had been
performed in 15.8%, and 63.0% of patients had significant
renal dysfunction (estimated glomerular filtration rate 60
ml/min). The mean logistic EuroSCORE was 22.9 
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125011.4%. The mean pressure gradient across the aortic valve
was 47.8  17.1 mm Hg, and the Diam-TEE was 22.1 
1.9 mm.
No significant differences were found in the baseline
characteristics except for the aortic valve area (0.63  0.15,
0.58 0.13, and 0.51 0.19 cm2, p 0.01). However, the
ortic valve area did not emerge as a predictor of post-
rocedural AR 2 (p  0.19). There were no significant
ifferences between the groups in terms of gradient or
aseline aortic and mitral regurgitation.
Procedural characteristics. The Edwards valve was im-
planted in 86.8% of patients and the CoreValve in 13.2%
(Table 2). The mean valve size was 25.6  2.1 mm, and the
most commonly used device was the Edwards 26-mm valve
(49.0%). Valve post-dilation was performed in 10.3% of
cases, namely in 30 recipients of the Edwards valve and 8
recipients of the CoreValve (8.6% vs. 14.8%, p  0.15).
wo patients (0.5%) survived the acute phase after devel-
ping aortic annulus rupture (1 transfemoral and 1 transaor-
ic case).
Following implantation, the mean aortic valve pressure
radient was 10.5  4.4 mm Hg. Device success was
chieved in 90.0% of cases, and the 30-day mortality rate
Table 1. Baseline Characteristics of the Study Population
Total
(N  400)
Grou
(n 
Age, yrs 83.4 6.1 83.0
Male 194 (48.5) 143 (47
Diabetes 92 (23.0) 68 (22
Hyperlipidemia 193 (48.3) 152 (50
Hypertension 276 (69.0) 200 (66
Current smoker 21 (5.3) 11 (3.7
NYHA functional class III/IV 347 (86.8) 256 (85
Coronary artery disease 237 (59.3) 172 (57
Previous CABG 63 (15.8) 48 (16
Peripheral artery disease 127 (31.8) 94 (31
Cerebrovascular disease 41 (10.3) 29 (9.7
COPD 124 (31.0) 88 (29
eGFR 60 ml/min. 249 (63.0) 177 (60
Logistic EuroSCORE, % 22.3 (17.1–30.3) 22.2 (16
STS score, % 7.9 (5.1–12.3) 7.4 (4.5
Aortic valve area, cm2 0.62 0.15 0.63
Mean pressure gradient, mm Hg 47.8 17.1 46.8
LVEF 40% 115 (28.8) 78 (26
Diam-TEE, mm 22.1 1.9 22.0
MDiam-CT, mm 23.6 2.0 23.5
Aortic regurgitation (0–4) 0.88 0.71 0.92
Mitral regurgitation (0–4) 1.02 0.73 1.00
Values are expressed as n (%), mean SD, or median (interquartile range).
BMI  body mass index; CABG  coronary artery bypass graft; COPD  chronic obstructive
transesophageal echography; eGFR  estimated glomerular filtration rate; LVEF  left ventricular
coronary intervention; STS Society of Thoracic Surgeons.as 9.5%.The Edwards valve was most frequently used in group 1
89.3%, 78.7%, and 83.3%, respectively, p  0.03) although
o significant differences in bioprosthesis size were recorded
etween the 3 groups (25.6  2.0%, 25.4  2.2%, and
5.5  2.2%, respectively, p  0.69).
The lower ratio between valve size and mDiam-CT was
n line with the increase in the grade of post-procedural AR
1.11  0.05, 1.09  0.05, and 1.08  0.21, respectively,
 0.03). There was a similar trend for valve size and
annulus diameter ratio as assessed by Diam-TEE and the
grade of post-procedural AR (1.16 0.07, 1.15 0.06, and
1.13  0.07, p  0.06).
Thirty-six patients had AR grade 3 or 4 before post-
dilation. Post-dilation was performed in 30 of these pa-
tients, and improvement was observed in 70% (21 patients;
6 into grade 0 or 1 and 15 into grade 2).
Of the 5 patients in whom annulus rupture occurred, 3
died during the procedure and were excluded from the study
cohort. Analysis was carried out in the 2 remaining patients
with annulus rupture who survived the acute phase (1
patient in group 1 and the other in group 2) (0.3%, 1.1%,
and 0%, p  0.44).
Interestingly, the post-procedural MR grade increased in
Group 2
(n  89)
Group 3
(n  12) p Value
84.5 5.4 82.8 5.0 0.12
43 (48.3) 8 (66.7) 0.44
19 (21.3) 5 (41.7) 0.29
34 (38.2) 7 (58.3) 0.09
68 (76.4) 8 (66.7) 0.23
9 (10.1) 1 (8.3) 0.05
79 (88.8) 12 (100) 0.29
56 (62.9) 9 (75.0) 0.35
13 (14.6) 2 (16.7) 0.88
26 (29.2) 7 (58.3) 0.12
9 (10.1) 3 (25.0) 0.23
28 (31.5) 7 (58.3) 0.10
64 (72.7) 8 (66.7) 0.09
) 24.9 (18.2–30.9) 21.1 (17.0–25.1) 0.28
8.3 (5.3–12.8) 8.3 (6.8–10.2) 0.81
0.58 0.13 0.51 0.19 0.01
48.8 19.6 65.5 26.2 0.08
33 (37.1) 3 (25.0) 0.13
22.2 2.1 22.5 2.1 0.53
24.1 2.0 22.9 2.7 0.27
0.83 0.74 0.42 0.52 0.06
1.07 0.81 1.00 0.71 0.73
nary disease; CT  computed tomography; Diam-TEE  aortic annulus diameter measured by
n fraction; MI  myocardial infarction; NYHA  New York Heart Association; PCI  percutaneousp 1
99)
6.3
.8)
.7)
.8)
.9)
)
.6)
.5)
.1)
.4)
)
.4)
.0)
.4–29.4
–12.3)
0.15
15.5
.2)
1.8
2.0
0.70
0.71
pulmo
ejectioparallel with the increase in the AR grade (0.78  0.73,
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12511.22  0.80, and 1.89  0.78, p  0.01 [group 1 vs. 2 and
vs. 3], p  0.03 [group 2 vs. 3]) (Fig. 1). Significant
mprovement between pre- and post-procedural MR was
bserved in group 1 (p  0.01): however, there was no
ignificant improvement in group 2 (p  0.19) and aggra-
ation of MR was recorded in group 3 (p  0.05).
At 30 days, there were no significant differences in acute
idney injury, major vascular complications, mortality, and
ombined safety endpoints.
Impact of post-procedural AR on long-term survival after
TAVI. The median follow-up period of this cohort was 297
ays (interquartile range: 101 to 607). In total, 109 patients
64 in group 1, 36 in group 2, and 9 in group 3) died during
he follow-up period. The cumulative incidence of mortality
t 2 years was 28.0%, 40.4%, and 75.0%, respectively. The
mpact of post-procedural AR on long-term mortality was
valuated.
Patients in group 3 had worse outcomes compared with
hose in group 1 (log-rank p  0.01) and group 2 (log-rank
 0.04) (Fig. 2A). Importantly, group 2 had a signifi-
antly worse outcome compared to group 1 (log-rank p 
.01) (Fig. 2A). The same findings were consistently ob-
Table 2. Procedural Characteristics of the Study Population
Total
(N  400)
Gr
(n 
Edwards valve 347 (86.8%) 267 (
Valve size, mm 25.6 2.1 25.6
Edwards 23 mm 127 (31.8%) 89 (
26 mm 196 (49.0%) 155 (
29 mm 24 (6.0%) 23 (
CoreValve 26 mm 11 (2.8%) 7 (
29 mm 39 (9.8%) 22 (
31 mm 3 (0.8%) 3 (
Valve/Diam-TEE ratio 1.15 0.07 1.16
Valve/mDiam-CT ratio 1.10 0.05 1.11
(n  180) (n 
Post-dilation 38 (10.3%) 13 (
Annulus rupture (survived) 2 (0.5%) 1 (
Post-implantation
Mean pressure gradient, mm Hg 10.5 4.4 10.6
LVEF, % 54.7 12.3 55.2
Mitral regurgitation (0–4) 0.91 0.78 0.78
Pacemaker 26 (7.9%) 16 (
Acute kidney injury 36 (9.0%) 22 (
Major vascular complication 35 (8.8%) 22 (
Device success 372 (90.0%) 286 (
30-Day mortality 38 (9.5%) 23 (
30-Day combined safety endpoint 82 (20.5%) 54 (
Hospital stay, days 9.5 (7.0–14.0) 10.0 (
Values are expressed as n (%), mean  SD, or median (interquartile range). *p Value 0.001 b
(Bonferroni test).
Abbreviations as in Table 1.erved in recipients of the Edwards valve (Fig. 2B) and the 0oreValve (Fig. 2C) alike, and in patients with 40%
Fig. 2D) left ventricular ejection fraction (LVEF) as in
hose with 40% LVEF (Fig. 2E). In group 2 (post-
rocedural AR grade 2), the impact of pre-procedural AR
as analyzed, and patients with no pre-procedural AR had
orse outcome compared with those who had pre-
rocedural AR (Fig. 3, log-rank p  0.01).
The impact of the change in the grade of AR (dAR:
ifference between pre- and post-procedural AR grade) was
lso evaluated (Fig. 4). The increase in dAR (i.e., worsening
f AR) also had a worse impact on mortality (log-rank p 
.01).
Predictors of long-term mortality. Predictors of long-term
mortality were evaluated. Following adjustment for other
variables, significant post-procedural AR (grade 2) (haz-
ard ratio [HR]: 1.70, 95% confidence interval [CI]: 1.13 to
2.56, p  0.01), conversion to open heart surgery (HR:
5.98, 95% CI: 2.61 to 13.70, p  0.01), major stroke (HR:
4.51, 95% CI: 1.90 to 10.71, p  0.01), acute kidney injury
HR: 2.19, 95% CI: 1.21 to 3.95, p  0.01), major vascular
omplication (HR: 1.73, 95% CI: 1.00 to 3.01, p  0.05),
ransfusion 4 (HR: 2.21, 95% CI: 1.17 to 4.17, p 
Group 2
(n  89)
Group 3
(n  12) p Value
70 (78.7%) 10 (83.3%) 0.03
25.4 2.2 25.5 2.2 0.69
34 (38.2%) 4 (33.3%) 0.03
35 (39.3%) 6 (50.0%)
1 (1.1%) 0
4 (4.5%) 0
15 (16.9%) 2 (16.7%)
0 0
1.15 0.06 1.13 0.07 0.06
1.09 0.05 1.08 0.21 0.03
(n  30) (n  2)
19 (24.1%) 6 (50.0%) 0.01
1 (1.1%) 0 0.44
10.5 3.8 9.3 3.9 0.53
53.1 12.8 54.7 19.9 0.44
1.22 0.80 1.89 0.78 0.01* 0.03†
9 (12.0%) 1 (8.3%) 0.32
12 (13.5%) 2 (16.7%) 0.13
11 (12.4%) 2 (16.7%) 0.21
86 (96.6%) 0 0.01
13 (14.6%) 2 (16.7%) 0.10
24 (27.0%) 4 (33.3%) 0.10
.0) 9.0 (7.0–12.0) 13 (7.0–24.5) 0.19
n group 1 and 2, and group 1 and 3 (Bonferroni test). †p value 0.029 between group 2 and 3oup 1
299)
89.3%)
 2.0
29.8%)
51.8%)
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1252to 1.04, p  0.01) were predictive of long-term mortality.
Chronic obstructive pulmonary disease and estimated glo-
merular filtration rate were associated with long-term mor-
tality by univariate analysis; however, these predictors were
no longer significant after adjustment for multivariable
analysis.
Discussion
This study demonstrates that post-procedural AR after
TAVI has a significant adverse effect on long-term out-
come, as evidenced in both Edwards valve and CoreValve
recipients, regardless of the type of bioprosthesis and
LVEF.
Impact of post-procedural AR after TAVI on long-term mor-
tality. In general, surgical aortic valve replacement is per-
formed after resection of the native aortic valve; this ensures
improved conformability of the aortic annulus with the
sewing ring of the surgical valve. The TAVI technique is
carried out by placing a stent-structured bioprosthesis and
compressing the native aortic valve without resecting it; this
may create a gap between the implanted bioprosthesis and
the aortic valve when the native valve or annulus are
calcified, thus causing post-procedural AR (4). As TAVI is
a relatively recent technique, long-term follow-up data are
not yet available, especially with respect to the durability of
the bioprostheses. The need for treatment of post-
Figure 1. Post-Procedural MR and Post-Procedural AR
The grade of post-procedural MR in each group is shown. *p  0.001,
**p  0.029 (Bonferroni test). AR  atrial regurgitation; MR  mitral
regurgitation.procedural AR must be rigorously assessed before decidingwhether post-dilation should be carried out after valve
deployment.
Significant post-procedural AR (grade 2/4) after TAVI
was recently identified as a predictor of late mortality in a
study from the Italian registry using the CoreValve (5).
Similar findings were reported in the German registry study
(12), which showed that AR grade 2/4 post TAVI based
n angiographic assessment was an independent predictor
f 30-day mortality. In this registry, the CoreValve was also
sed in 82% of cases. These previous reports mainly con-
erned the cohort of CoreValve recipients; moreover, they
id not contain any substantial data on the impact of AR
rade 2 (compared with absence of AR) versus no AR on
he severity of the outcome. In the study reported here, we
learly observed that not only AR grade 3 or 4, but also AR
rade 2 had a significant impact on the long-term outcome
Fig. 1A, log-rank p 0.01, group 1 vs. 2), regardless of the
type of bioprosthesis used for TAVI (Figs. 2B and 2C).
Furthermore, this finding was consistently recorded, not
only in patients with reduced LVEF (Fig. 2E), but also in
those with preserved LVEF (Fig. 2D). The same observa-
tion was briefly reported in the recently published 2-year
follow-up results of the cohort A of the PARTNER
(Placement of AoRTic TraNscathetER Valve) trial (13),
and our data support these findings. We also analyzed the
impact of “the change in the degree of AR between pre- and
post-procedure” on mortality. Notably, the “change in the
degree of AR” observed in the study reported here had a
similar impact on mortality (Fig. 3, log-rank p  0.03, Fig. 4,
log-rank p  0.01) as did the absolute value of post-
procedural AR grade (Fig. 2, log-rank p  0.01). Our
results convey important clinical implications by demon-
strating that not only post-procedural AR grade 3 or 4, but
also AR grade 2, should be prevented by meticulous
pre-procedural evaluation of the annulus size and treated by
using post-dilation when indicated (14).
We recently reported that CT-guided valve selection
allows better appreciation of the 3-dimensional structure of
the aortic annulus and is potentially associated with a lower
incidence of significant post-procedural AR (6). Routine
implementation of this strategy may prevent the occurrence
of this underestimated complication. Because post-dilation
carries an inherent risk of annulus rupture and may promote
accelerated bioprosthesis degeneration, excessive balloon
oversizing should be avoided.
Interestingly, post-procedural MR increased in parallel
with the degree of post-procedural AR (0.78  0.73,
1.22  0.80, and 1.89  0.78, in groups 1, 2, and 3,
respectively, Fig. 1) despite the absence of significant
differences in pre-procedural MR. The degree of MR
usually remains unchanged or even improves after TAVI,
and aggravation of MR is a rare occurrence (15,16). In our
study, improvement in MR was observed only in group 1;
there was no improvement in group 2, and deterioration was
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1253Figure 2. Survival Curves by Post-Procedural AR
Survival curves for post-procedural AR grade: 0 or 1 (group 1, blue), 2 (group 2, green), and 3 to 4 (group 3, red). Cumulative survival rates were calculated by
the Kaplan-Meier method and compared with the log-rank test. (A) Survival curves by post-procedural AR in the whole cohort. (B) Survival curves in the patients
who received the Edwards valve. (C) Survival curves in the patients who received the CoreValve. (D) Survival curves in the patients who had LVEF 40%. (E) Sur-
vival curves in the patients who had LVEF 40%. AR  atrial regurgitation; LVEF  left ventricular ejection fraction.
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1254observed in group 3. The mechanism underlying this
finding is unclear. However, impaired hemodynamics and
worsening heart failure resulting from post-procedural AR
may aggravate MR and lead to higher mortality. The
position of the bioprosthesis can also have an impact on AR
and possibly on MR, which may be one possible explanation
for our findings and remains to be explored.
Generally, AR grade 2 in itself does not seem to signif-
icantly impact clinical outcomes. However, the reason why
post-procedural AR grade 2 influences the rate of mortality
remains unclear. A hypertrophic left ventricle that has been
exposed to long-term pressure overload may not be able to
adapt abruptly to a diastolic overload, even in the presence
of AR grade 2/4, especially when no pre-procedural AR has
been observed (Fig. 3). The increase in post-procedural MR
in parallel with AR (Fig. 1) may reflect the overload due to
post-procedural AR.
In our cohort, the CoreValve was more frequently used in
groups 2 and 3, where the incidence of significant AR was
39.6%. The reason for this has not been identified; however,
the fact that the operators were less experienced in the use
of the CoreValve (53 of 400 cases) may have had an impact
on the higher incidence of significant AR. Indeed, whereas
significant AR was observed in 33.5% of the first half of
the Edwards valve recipients, it decreased to 12.6% in the
remaining half of the patients, presumably due to the
Figure 3. Survival Curves by the Pre-Procedural AR Grade in Group 2
Survival curves for the patients with no pre-procedural AR (pink) and those
who had pre-procedural AR (blue). Cumulative survival rates calculated by
the Kaplan-Meier method and compared with the log-rank test. AR  atrial
regurgitation.introduction of multidetector CT enabling accurate mea-surement. Furthermore, the CoreValve is generally used in
patients with a larger annulus, including the upper limit of
annulus size. This valve selection bias could have impacted
these results.
Recently, the “AR index,” which is derived from hemo-
dynamic parameters, emerged as a new method for evalu-
ating post-procedural AR and predicting 1-year mortality.
This approach can prove useful in providing extra diagnostic
information to complement the echocardiographic data (17).
Predictor of long-term mortality. In previously published
eports (5–18,19), significant post-procedural AR was iden-
ified as 1 of the predictors of long-term mortality (5,20), as
as acute kidney injury (18,19). Our results are in line with
hese findings.
As suggested in our recent report (10), male sex was also
dentified as a predictor in the current study. The CoreValve
as used more frequently in groups 2 and 3 and the
ssociation between post-procedural AR and this biopros-
hesis has also been reported previously (12). However, the
ype of bioprosthesis used for TAVI was not identified as a
redictor of long-term mortality (Table 3).
Study limitations. Our study reports a retrospective single-
center TAVI cohort of limited size. We opted to include
recipients of both the Edwards valve and the CoreValve, as
this mixed cohort reflected our real clinical experience. The
quantification of paravalvular aortic regurgitation was some-
times difficult due to the confined nature of the jet(s) and
the absence of an echo core laboratory; however, the
assessment was achieved according to the guidelines by 2
Figure 4. Survival Curves by the Increase in AR
Survival curves for the change of AR: improved (purple), no or little
change (green), and worsened (orange). Cumulative survival rates calcu-
lated by the Kaplan-Meier method and compared with the log-rank test.
AR  atrial regurgitation.
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1255independent experienced echocardiographers. The mecha-
nism of AR worsening was not analyzed in detail, because
the focus of the study was the clinical impact of AR
regardless of its precise cause. The occurrence and impact of
aortic regurgitation over time during follow-up was not
analyzed in this paper as this was not the aim of this study.
Further studies of larger patient populations are required to
confirm our results. Both Edwards Sapien and Sapien-XT
valves were included, despite the differences in material
(stainless steel for the former and cobalt-chromium for the
latter).
Conclusions
Significant post-procedural AR after TAVI was identified
as an independent predictor of long-term mortality. It was
shown to have a significant adverse effect on long-term
outcome regardless of the type of bioprosthesis used and
LVEF. AR grade 2 was associated with deteriorated out-
come compared with AR grade 0 or 1. Careful valve
selection based on meticulous pre-procedural annulus sizing
and post-dilation when required to avoid, not only grade 3
or 4, but also post-procedural AR grade 2, may contribute to
improving the clinical outcome of TAVI patients.
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Table 3. Predictors of Long-Term Mortality
p Value
Univariate
Hazard rat
Post-procedural aortic regurgitation 2/4 0.01 1.75
Conversion to open heart surgery 0.01 6.58
Major stroke 0.01 4.37
Acute kidney injury 0.01 2.65
Major vascular complication 0.01 2.71
Transfusion 4 units 0.01 3.66
Logistic EuroSCORE 0.01 1.02
eGFR 60 ml/min. 0.01 1.87
COPD 0.05 1.41
Male sex 0.07 1.36
Previous CABG 0.12 1.45
Left ventricular ejection fraction 0.32 1.21
Age 0.32 1.02
Type of bioprosthesis 0.59 0.87
CI confidence interval; other abbreviations as in Tables 1 and 2.REFERENCES
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